Identification and Characterization of the Infectious Disease Risks of Human Cells, Tissues, and Cellular and Tissue-Based Products; Public Workshop; Correction, 14366-14367 [2017-05417]
Download as PDF
sradovich on DSK3GMQ082PROD with NOTICES
14366
Federal Register / Vol. 82, No. 52 / Monday, March 20, 2017 / Notices
ken.sandler@gsa.gov to register to attend
the meeting and/or listen in to any or all
of these conference calls. To attend the
meeting and/or conference calls, submit
your full name, organization, email
address, and phone number, and which
you would like to attend. Requests to
attend the June 7, 2017 meeting must be
received by 5:00 p.m., EDT, on Friday,
May 26, 2017. Requests to listen in to
the conference calls must be received by
5:00 p.m., EDT, on Tuesday, April 4,
2017. (GSA will be unable to provide
technical assistance to any listener
experiencing technical difficulties.
Testing access to the Web meeting site
in advance of calls is recommended.)
Contact Ken Sandler at ken.sandler@
gsa.gov to register to comment during
the June 7, 2017 meeting public
comment period. Registered speakers/
organizations will be allowed a
maximum of five minutes each, and will
need to provide written copies of their
presentations. Requests to comment at
the meeting must be received by 5:00
p.m., EDT, on Friday, May 26, 2017.
Written comments also may be provided
to Mr. Sandler at ken.sandler@gsa.gov
by the same deadline.
Background: The Administrator of
GSA established the Committee on June
20, 2011 (Federal Register/Vol. 76, No.
118) pursuant to Section 494 of the
Energy Independence and Security Act
of 2007 (EISA, 42 U.S.C. 17123). Under
this authority, the Committee provides
independent policy advice and
recommendations to GSA to increase
the economic and operational
performance of the federal building
portfolio and its positive impact on
organizational effectiveness, human
health and wellbeing.
The Committee has recently proposed
two new task groups. The High
Performance Building Adoption task
group will pursue the motion of a
committee member to provide
recommendations to ‘‘accelerate the
adoption of high performance [Federal]
buildings.’’ The Health and Wellness
task group will pursue the motion of a
committee member to ‘‘develop
guidelines to integrate health and
wellness features into government
facilities programs.’’
The conference calls will allow the
task groups to coordinate the
development of consensus
recommendations to the full Committee,
which will, in turn, decide whether to
proceed with formal advice to GSA
based upon these recommendations.
June 7, 2017 Meeting Agenda:
• Welcome, Introductions, Updates &
Plans for Today
• High Performance Building Adoption:
Task Group Report & Discussion
VerDate Sep<11>2014
18:36 Mar 17, 2017
Jkt 241001
• Working Lunch (with Presentation)
• Health and Wellness: Task Group
Report & Discussion
• Topics Proposed by Committee
Members
• Public Comment Period
• Closing comments
• Adjourn
Detailed agendas, background
information, and updates for the
meeting and conference calls will be
posted on GSA’s Web site at https://
www.gsa.gov/gbac.
Meeting Access: The Committee will
convene its June 7, 2017 meeting at
GSA, Room 1153, 1800 F Street NW.,
Washington DC 20405, and the site is
accessible to individuals with
disabilities.
Dated: March 13, 2017.
Kevin Kampschroer,
Federal Director, Office of Federal HighPerformance Green Buildings, General
Services Administration.
[FR Doc. 2017–05416 Filed 3–17–17; 8:45 am]
BILLING CODE 6820–14–P
OFFICE OF GOVERNMENT ETHICS
Request for Public Input on the
Application of the Criminal Conflict of
Interest Prohibition to Certain
Beneficial Interests in Discretionary
Trusts; Extension of Comment Period
AGENCY:
Office of Government Ethics
(OGE).
Notice of request for public
comments; extension of comment
period.
ACTION:
On January 3, 2017, OGE
published in the Federal Register, 82 FR
122 (Jan. 3, 2017), a request for public
input on the application of the criminal
conflict of interest prohibition to certain
beneficial interests in discretionary
trusts. The public comment period
closed on March 6, 2017. OGE is
extending the comment period to April
20, 2017.
DATES: To be assured consideration,
comments must be received at the
address provided below, by April 20,
2017, though OGE may have some
limited ability to review late
submissions if workload and other
considerations permit.
ADDRESSES: You may submit comments,
in writing, to OGE regarding this notice
and request by any of the following
methods:
Email: usoge@oge.gov. Include the
reference ‘‘Request for Input on
Discretionary Trusts’’ in the subject line
of the message.
Fax: (202) 482–9237.
SUMMARY:
PO 00000
Frm 00024
Fmt 4703
Sfmt 4703
Mail/Hand Delivery/Courier: U.S.
Office of Government Ethics, Suite 500,
1201 New York Avenue NW.,
Washington, DC 20005–3917, Attention:
‘‘Request for Input on Discretionary
Trusts.’’
Instructions: All submissions must
include OGE’s agency name and the
words ‘‘Discretionary Trusts.’’ All
comments, including attachments and
other supporting materials, will become
part of the public record and subject to
public disclosure. Comments may be
posted on OGE’s Web site, www.oge.gov.
Sensitive personal information, such as
account numbers or Social Security
numbers, should not be included.
Comments generally will not be edited
to remove any identifying or contact
information.
FOR FURTHER INFORMATION CONTACT:
Jennifer A. Matis, Assistant Counsel,
Office of Government Ethics, Suite 500,
1201 New York Avenue NW.,
Washington, DC 20005–3917;
Telephone: 202–482–9300; TTY: 800–
877–8339; FAX: 202–482–9237.
SUPPLEMENTARY INFORMATION: To be
considered, any submission exceeding
five (5) pages in length must include a
one-page summary of key points and
conclusions. Commenters are requested
to state briefly the nature of their
expertise in trust law. A copy of the
original notice of request for public
comments, 82 FR 122 (Jan. 3, 2017), is
available at: https://www.gpo.gov/fdsys/
pkg/FR-2017-01-03/pdf/2016-31583.pdf.
Approved: March 14, 2017.
Walter M. Shaub, Jr.,
Director, U.S. Office of Government Ethics.
[FR Doc. 2017–05454 Filed 3–17–17; 8:45 am]
BILLING CODE 6345–03–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2016–N–0001]
Identification and Characterization of
the Infectious Disease Risks of Human
Cells, Tissues, and Cellular and
Tissue-Based Products; Public
Workshop; Correction
AGENCY:
Food and Drug Administration,
HHS.
Notice of public workshop;
correction.
ACTION:
The Food and Drug
Administration (FDA) is correcting a
notice that appeared in the Federal
Register of Thursday, December 29,
2016. The document announced a
SUMMARY:
E:\FR\FM\20MRN1.SGM
20MRN1
Federal Register / Vol. 82, No. 52 / Monday, March 20, 2017 / Notices
public workshop entitled ‘‘Identification
and Characterization of the Infectious
Disease Risks of Human Cells, Tissues,
and Cellular and Tissue-based
Products.’’ The document was
published with an error in the Web site
address to access the transcript of the
workshop. This document corrects that
error.
FOR FURTHER INFORMATION CONTACT:
Monica Kapoor, Center for Biologics
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 3111C,
Silver Spring, MD 20993,
CBERPublicEvents@fda.hhs.gov; or Staci
Revette, Center for Biologics Evaluation
and Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 71, Rm. 3109B, Silver
Spring, MD 20993, CBERPublicEvents@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In the
Federal Register of Thursday, December
29, 2016, in FR Doc. 2016–31628, on
page 96008, the following correction is
made:
On page 96008, in the second column
under the Transcripts caption of section
III, Participating in the Public
Workshop, the third sentence in the
fourth paragraph is corrected to read,
‘‘Please be advised that as soon as a
transcript of the public workshop is
available, it will be accessible at: https://
www.fda.gov/BiologicsBloodVaccines/
NewsEvents/
WorkshopsMeetingsConferences/
ucm525001.htm.’’
Dated: March 14, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017–05417 Filed 3–17–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2016–N–4620]
Food and Drug Administration,
sradovich on DSK3GMQ082PROD with NOTICES
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or Agency) is
announcing an opportunity for public
comment on the proposed collection of
certain information by the Agency.
Under the Paperwork Reduction Act of
1995 (the PRA), Federal Agencies are
SUMMARY:
VerDate Sep<11>2014
18:36 Mar 17, 2017
Jkt 241001
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov/. Follow
the instructions for submitting
comments. Comments submitted
electronically, including attachments, to
https://www.regulations.gov/ will be
posted to the docket unchanged.
Because your comment will be made
public, you are solely responsible for
ensuring that your comment does not
include any confidential information
that you or a third party may not wish
to be posted, such as medical
information, your or anyone else’s
Social Security number, or confidential
business information, such as a
manufacturing process. Please note that
if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov/.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Medical Devices;
Reports of Corrections and Removals
AGENCY:
required to publish notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information, and
to allow 60 days for public comment in
response to the notice. This notice
solicits comments on the submission of
reports of corrections and removals that
are associated with medical and
radiation emitting products regulated by
FDA’s Center for Devices and
Radiological Health.
DATES: Submit either electronic or
written comments on the collection of
information by May 19, 2017.
ADDRESSES: You may submit comments
as follows:
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Division of Dockets
Management, FDA will post your
comment, as well as any attachments,
except for information submitted,
marked and identified, as confidential,
if submitted as detailed in
‘‘Instructions.’’
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
14367
Instructions: All submissions received
must include the Docket No. FDA–
2016–N–4620 for ‘‘Agency Information
Collection Activities; Proposed
Collection; Comment Request; Medical
Devices; Reports of Corrections and
Removals.’’ Received comments will be
placed in the docket and, except for
those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov/ or at the
Division of Dockets Management
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov/. Submit
both copies to the Division of Dockets
Management. If you do not wish your
name and contact information to be
made publicly available, you can
provide this information on the cover
sheet and not in the body of your
comments and you must identify this
information as ‘‘confidential.’’ Any
information marked as ‘‘confidential’’
will not be disclosed except in
accordance with 21 CFR 10.20 and other
applicable disclosure law. For more
information about FDA’s posting of
comments to public dockets, see 80 FR
56469, September 18, 2015, or access
the information at: https://www.fda.gov/
regulatoryinformation/dockets/
default.htm.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov/ and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Division of Dockets
Management, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: FDA
PRA Staff, Office of Operations, Food
and Drug Administration, Three White
Flint North, 10A63, 11601 Landsdown
St., North Bethesda, MD 20852,
PRAStaff@fda.hhs.gov.
E:\FR\FM\20MRN1.SGM
20MRN1
Agencies
[Federal Register Volume 82, Number 52 (Monday, March 20, 2017)]
[Notices]
[Pages 14366-14367]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-05417]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2016-N-0001]
Identification and Characterization of the Infectious Disease
Risks of Human Cells, Tissues, and Cellular and Tissue-Based Products;
Public Workshop; Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of public workshop; correction.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is correcting a notice
that appeared in the Federal Register of Thursday, December 29, 2016.
The document announced a
[[Page 14367]]
public workshop entitled ``Identification and Characterization of the
Infectious Disease Risks of Human Cells, Tissues, and Cellular and
Tissue-based Products.'' The document was published with an error in
the Web site address to access the transcript of the workshop. This
document corrects that error.
FOR FURTHER INFORMATION CONTACT: Monica Kapoor, Center for Biologics
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 3111C, Silver Spring, MD 20993,
CBERPublicEvents@fda.hhs.gov; or Staci Revette, Center for Biologics
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 3109B, Silver Spring, MD 20993,
CBERPublicEvents@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In the Federal Register of Thursday,
December 29, 2016, in FR Doc. 2016-31628, on page 96008, the following
correction is made:
On page 96008, in the second column under the Transcripts caption
of section III, Participating in the Public Workshop, the third
sentence in the fourth paragraph is corrected to read, ``Please be
advised that as soon as a transcript of the public workshop is
available, it will be accessible at: https://www.fda.gov/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/ucm525001.htm.''
Dated: March 14, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017-05417 Filed 3-17-17; 8:45 am]
BILLING CODE 4164-01-P